PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer-Reference-Cited by-同舟云学术

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer

Published:2022-06-24 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Liu Peng¹²,Chen Jianzhou³,Zhao Liwei¹²,Hollebecque Antoine⁴,Kepp Oliver¹²^ORCID,Zitvogel Laurence³⁴⁵⁶,Kroemer Guido¹²⁷

Affiliation:

1. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France

2. Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138 and CNRS SNC 5096, Institut Universitaire de France, Paris, France

3. INSERM U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France

4. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France

5. Gustave Roussy, ClinicObiome, Villejuif, France

6. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France

7. Institut du Cancer Paris CARPEM, Department of Biology, APHP, Hôpital Européen Georges Pompidou, Paris, France

Funder

The author(s) reported there is no funding associated with the work featured in this article

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2093518

Reference67 articles.

1. The rediscovery of platinum-based cancer therapy

2. Cisplatin in cancer therapy: Molecular mechanisms of action

3. Links between cancer metabolism and cisplatin resistance

4. The resurgence of platinum-based cancer chemotherapy

5. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance;Molecular Cancer;2024-09-06

2. Targeted co-delivery of rapamycin and oxaliplatin by liposomes suppresses tumor growth and metastasis of colorectal cancer;Biomedicine & Pharmacotherapy;2024-09

3. Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma;OncoImmunology;2024-05-27

4. Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy;Biomedicine & Pharmacotherapy;2024-05

5. Ferroptosis and HMGB2 induced calreticulin translocation required for immunogenic cell death are controlled by the nuclear exporter XPO1;2024-04-08